STRO News and Press, Sutro Biopharma Inc.

2024-05-20 09:58:08 ET More on premarkets gainers & stock Crown ElectroKinetics Corp. (CRKN) Q1 2024 Earnings Call Transcript Crown ElectroKinetics Corp. (CRKN) Q4 2023 Earnings Call Transcript Financial information for Crown ElectroKinetics Financial inf...

2024-05-13 17:18:12 ET More on Sutro Biopharma BofA starts Sutro at buy, cites ovarian cancer drug candidate Sutro Biopharma prices $75M underwritten offering Seeking Alpha’s Quant Rating on Sutro Biopharma Historical earnings data for Sutro Biopharma ...

- Investigational New Drug application for non-small cell lung cancer trial with luvelta cleared by U.S. Food and Drug Administration; Phase 2 on track to begin dosing in the second half of 2024 - - Patient expansion phase well underway in Phase 2 study of luvelta in combination with be...

2024-05-08 11:28:27 ET More on Sutro Biopharma Sutro Biopharma prices $75M underwritten offering Ipsen secures exclusive global rights of Sutro Biopharma's STRO-003 ADC Seeking Alpha’s Quant Rating on Sutro Biopharma Historical earnings data for Sutro ...

– Part 2 of REFRαME-O1, the registration-directed study of luvelta for patients with platinum-resistant ovarian cancer (PROC), is open for enrollment – – Planned 50 patients in Dose-Optimization (Part 1) of REFRαME-O1 have been enrolled and are in foll...

2024-04-17 17:01:03 ET Gainers: Vanda Pharmaceuticals  ( VNDA ) +7% . Sutro Biopharma ( STRO ) +5% . CureVac  ( CVAC ) +5% . CorMedix  ( CRMD ) +4% . Bank OZK ( OZK ) +4% . Losers: Omega Therapeutics ( OM...

2024-04-05 18:31:56 ET Summary Ipsen S.A. is a pharmaceutical company focused on oncology, rare disease, and neuroscience, with a portfolio of commercial drug products. The company generated $3.4bn in revenues in 2023, with a core consolidated net profit of $830m. Ipsen typica...

2024-04-03 17:00:02 ET Jay Olson from Oppenheimer issued a price target of $10.00 for STRO on 2024-04-03 14:01:00. The adjusted price target was set to $10.00. At the time of the announcement, STRO was trading at $5.09. The overall price target consensus is at $14.50 wit...

2024-04-03 08:00:08 ET Edward Tenthoff from Piper Sandler issued a price target of $11.00 for STRO on 2024-04-03 06:48:00. The adjusted price target was set to $11.00. At the time of the announcement, STRO was trading at $5.09. The overall price target consensus is at $1...

2024-04-02 06:36:56 ET More on Sutro Biopharma Ipsen secures exclusive global rights of Sutro Biopharma's STRO-003 ADC Seeking Alpha’s Quant Rating on Sutro Biopharma Historical earnings data for Sutro Biopharma Financial information for Sutro Biopharm...